Zoetis Inc. (ZTS) — Fair Value Analysis

Base-case fair value (P50): $87.80 · Current price: $73.79 · Verdict: Undervalued

The Verdict on ZTS

Based on extensive Monte Carlo simulations, Zoetis (ZTS) is currently deemed Fairly Valued. While its current market price of $73.79 sits below our median fair value (P50) of $87.80, the implied +19.0% upside does not significantly tip the scales towards undervaluation within the context of its risk profile. Our analysis, which models thousands of potential future scenarios, suggests ZTS is trading reasonably close to its intrinsic value, reflecting the market's current assessment of its operational and financial health.

How ZTS stacks up against Healthcare

As a significant player in the Healthcare sector, ZTS's quality tier is assessed as average when comparing its operational and financial health against its industry peers. This average rating is factored into our Monte Carlo simulations, influencing the range and probability distribution of its fair value outcomes. The median fair value of $87.80 indicates a potential upward movement from the current $73.79, but this modest +19.0% aligns with the expectation for a company with an average quality standing within a stable sector.

What this means for investors

For investors considering ZTS at its current price of $73.79, the Monte Carlo simulations suggest a balanced outlook. The calculated median fair value of $87.80 points to a potential +19.0% without a strong conviction of deep undervaluation. While an upside scenario is modeled, investors should note the company's average quality tier within the Healthcare sector. To gain a complete picture of ZTS's potential, including specific downside and bull case scenarios derived from the full Monte Carlo distribution, consider a free FairCurve account. Sign up for FairCurve to see the full bear/bull distribution and track ZTS's fair value as new fundamentals are released.